{"doi":"10.1038/s41417-024-00815-2","title":"Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors","abstract":null,"journal":"Cancer Gene Therapy","year":2024,"id":639845,"datarank":0.8869775234709275,"base_score":3.4339872044851463,"endowment":3.4339872044851463,"self_citation_contribution":0.515098080672772,"citation_network_contribution":0.37187944279815555,"self_endowment_contribution":0.515098080672772,"citer_contribution":0.37187944279815555,"corpus_percentile":null,"corpus_rank":null,"citation_count":30,"citer_count":30,"citers_with_citation_signal":14,"citers_with_endowment":14,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1662718,"name":"Clarissa Mujacic","orcid":null,"position":1,"is_corresponding":false},{"id":1662719,"name":"Emilia Di Giovanni","orcid":null,"position":2,"is_corresponding":false},{"id":1662720,"name":"Maria Concetta Vitale","orcid":null,"position":3,"is_corresponding":false},{"id":1662721,"name":"Carla Ferrante Bannera","orcid":null,"position":4,"is_corresponding":false},{"id":1662722,"name":"Ugo Randazzo","orcid":null,"position":5,"is_corresponding":false},{"id":1505181,"name":"Silvia Contino","orcid":null,"position":6,"is_corresponding":false},{"id":1662723,"name":"Marco Bono","orcid":"0000-0001-7169-3463","position":7,"is_corresponding":false},{"id":1662724,"name":"Valerio Gristina","orcid":null,"position":8,"is_corresponding":false},{"id":1662725,"name":"Antonio Galvano","orcid":null,"position":9,"is_corresponding":false},{"id":1662726,"name":"Alessandro Perez","orcid":null,"position":10,"is_corresponding":false},{"id":1662727,"name":"Giuseppe Badalamenti","orcid":null,"position":11,"is_corresponding":false},{"id":1598365,"name":"Antonio Russo","orcid":"0000-0002-4370-2008","position":12,"is_corresponding":false},{"id":1662728,"name":"Viviana Bazan","orcid":null,"position":13,"is_corresponding":false},{"id":1662729,"name":"Lorena Incorvaia","orcid":null,"position":14,"is_corresponding":false},{"id":1662717,"name":"Tancredi Didier Bazan Russo","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors","abstract":"The most remarkable finding in synthetic lethality (SL) is the hypersensitivity to PARP inhibitors (PARPis) of the tumors harboring defects in genes involved in homologous repair (HR) such as BRCA1/2. Despite initial responsiveness to PARPi, the penetrance of the synthetic lethal interactions between BRCA1/2 genes and PARPi is incomplete. Thus, a significant proportion of HR-defective tumors experience intrinsic or acquired resistance, representing a key challenge of clinical research. An expanded concept of SL is opening new ways and includes novel forms of genetic interactions, investigating not only traditional SL of pairs genes but also SL between biological pathways that regulate the same essential survival cell function. In this context, recent research showed that HR and theta-mediated end-joining (TMEJ) pathways exhibit SL. DNA polymerase theta (Polθ) is encoded by the POLQ gene and is a key component of the TMEJ, an essential backup pathway, intrinsically mutagenic, to repair resected double-strand breaks (DSBs) when the non-homologous end joining (NHEJ) and HR are impaired. Polθ is broadly expressed in normal tissues, overexpressed in several cancers, and typically associated with poor outcomes and shorter relapse-free survival. Notably, HR-deficient tumor cells present the characteristic mutational signatures of the error-prone TMEJ pathway. According to this observation, the loss of HR proteins, such as BRCA1 or BRCA2, contributes to increasing the TMEJ-specific genomic profile, suggesting synthetic lethal interactions between loss of the POLQ and HR genes, and resulting in the emerging interest for Polθ as a potential therapeutic target in BRCA1/2-associated tumors.This review summarizes the converging roles of the POLQ and HR genes in DNA DSB repair, the early-stage clinical trials using Polθ inhibitor to treat HR-defective tumors and to overcome BRCA-reversion mutations responsible for therapeutic resistance, and the novel pleiotropic effects of Polθ, paving the way for the development of unexplored synthetic lethality strategies.","is_dataset_classified":null,"base_score":3.4339872044851463,"endowment":3.4339872044851463,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39122831","pmcid":"PMC11567890","openalex_id":"https://openalex.org/W4401455145","authors":[],"funders":[],"total_grants":0,"fwci":5.3914,"citation_percentile":0.97227571,"influential_citations":0,"citation_trend":[{"year":2025,"count":15},{"year":2026,"count":15}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://www.nature.com/articles/s41417-024-00815-2.pdf","host_type":"journal"},{"url":"https://doi.org/10.1038/s41417-024-00815-2","host_type":"HYBRID"},{"url":"https://www.nature.com/articles/s41417-024-00815-2.pdf","host_type":"publisher"},{"url":"https://www.nature.com/articles/s41417-024-00815-2","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39122831","host_type":"repository"},{"url":"https://hdl.handle.net/10447/652553","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11567890","host_type":"repository"},{"url":"https://iris.unipa.it/bitstream/10447/652553/2/pol%20theta.pdf","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11567890/pdf/41417_2024_Article_815.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11567890","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11567890?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["PARP inhibition in cancer therapy","DNA Repair Mechanisms","Cell death mechanisms and regulation","Medicine","Biology","Humans","DNA Polymerase theta","DNA-Directed DNA Polymerase","Neoplasms","Synthetic Lethal Mutations","Homologous Recombination","Animals","Poly(ADP-ribose) Polymerase Inhibitors","BRCA2 Protein","DNA End-Joining Repair"],"mesh_terms":["Poly(ADP-ribose) Polymerase Inhibitors","Synthetic Lethal Mutations","DNA Polymerase theta","Animals","DNA-Directed DNA Polymerase","Humans","Neoplasms","BRCA2 Protein","Homologous Recombination","DNA End-Joining Repair"],"keywords":["Homologous recombination","Homologous chromosome","Recombination","Genetics","Biology","Computational biology","Cancer research","Molecular biology","Gene"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"},{"name":"pdb"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T02:56:16.877325Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}